Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 501–600 of 789
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.07.008 · Cited by 15
Takasu, T., Hayashizaki, Y., Hirosumi, J., Minoura, H., Amino, N., Kurosaki, E., & Takakura, S. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00964 · Cited by 11
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
Taberner-Cortés, A., Vinué, Á., Herrero-Cervera, A., Aguilar-Ballester, M., Real, J. T., Burks, D. J., Martínez‐Hervás, S., & Navarro, H. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239216 · Cited by 12
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Self-citationSGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
SGLT2 inhibitors: cardiorenal metabolic drugs for the ages
DeFronzo, R. A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177625 · Cited by 10
“…note, the increase in EGP was associated with an increase in plasma glucagon concentration and a decline in plasma insulin concentration, and the increase in EGP off-set by approximately 50% the amount of glucose excreted in the urine (5–7), thereby blunting the decrease in fasting plasma glucose…”
Self-citationLin, B., Guo, X., Lü, W., Niu, R. L., Zeng, X., Chen, Z., Wu, C., & Liu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176742 · Cited by 12
Ueno, H., Nakazato, H., Ebihara, E., Noma, K., Kawano, T., Nagamine, K., Sakoda, H., & Nakazato, M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0366-8 · Cited by 10
Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Correale, M., Petroni, R., Coiro, S., Antohi, E., Monitillo, F., Leone, M., Triggiani, M., Ishihara, S., Düngen, H., Sarwar, C. M. S., et al. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10107-8 · Cited by 13
Where to for precision treatment of HNF1A-MODY?
Bonner, C., & Saponaro, C. (2022) · Diabetologia · doi:10.1007/s00125-022-05696-4 · Cited by 11
Qiu, R., Balis, D. A., Capuano, G. A., Xie, J., & Meininger, G. E. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0201-z · Cited by 11
Melmer, A., Kempf, P., Lunger, L., Pieber, T. R., Mader, J. K., Stettler, C., Tilg, H., Ebenbichler, C. F., & Laimer, M. W. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13439 · Cited by 10
Menghoum, N., Oriot, P., Hermans, M. P., & Mariage, J.-L. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.12.006 · Cited by 11
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus
Orime, K., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1803280 · Cited by 13
Hughes, C. B., Mussman, G. M., Ray, P., Bunn, R. C., Cornea, V., Thrailkill, K. M., Fowlkes, J. L., & Popescu, I. R. (2021) · Cell and Tissue Research · doi:10.1007/s00441-020-03358-8 · Cited by 12
SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
Granata, A. R. M., Pesce, F., Iacoviello, M., Anzaldi, M., Amico, F., Catalano, M. R., Leonardi, G., Gatta, C., Costanza, G., Corrao, S., et al. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.867075 · Cited by 13
Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise
Herring, R. A., Parsons, I., Shojaee‐Moradie, F., Stevenage, M., Jackson, N., MANDERS, R. J. F., Umpleby, A. M., Fielding, B. A., Davies, M. J., & Russell-Jones, D. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac617 · Cited by 10
Maranghi, M., Carnovale, A., Durante, C., Tarquini, G., Tiseo, G., & Filetti, S. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.986457 · Cited by 12
Moon, J. S., Park, I. R., Kim, H. J., Chung, C. H., Won, K. C., Han, K. A., Park, C., Won, J. C., Kim, D. J., Koh, G. P., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0387 · Cited by 9
“However, little is known regarding the glucagon changes after long-term treatment of at least 24 weeks or more [11,24].”
Sodium–glucose cotransporter 2 inhibitors and diabetic ketoacidosis
Bloomgarden, Z. T. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12353 · Cited by 11
Yoshimura, Y., Hashimoto, Y., Okada, H., Takegami, M., Nakajima, H., Miyoshi, T., Yoshimura, T., Yamazaki, M., Hamaguchi, M., & Fukui, M. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14054 · Cited by 11
Genetic and clinical characterization of familial renal glucosuria
Xu, L., Zhao, R., Zhao, Y., Tang, X., Si, N., Guo, X., Yue, C., Nie, M., & Chen, L. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad265 · Cited by 14
“Increased glucagon level after SGLT2 inhibition has been re-ported in clinical studies [11 , 12 ], and it may play a role in the development of euglycemia diabetic ketoacidosis [13 ].”
BackgroundLyu, Y. S., Hong, S., Lee, S. E., Cho, B. Y., & Park, C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02155-9 · Cited by 10
“The pooled clinically relevant data from the individual trials were compared between the enavogliflozin and dapagliflozin groups at baseline and at weeks 6, 12, 18, and 24.”
BackgroundMethodMiyauchi, M., Toyoda, M., & Fukagawa, M. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7945 · Cited by 9
Rizos, C. V., Filippatos, T. D., & Elisaf, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418325 · Cited by 10
Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
New insights into cellular links between sodium–glucose cotransporter‐2 inhibitors and ketogenesis
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30327 · Cited by 9
Sato, M., Tamura, Y., Kaga, H., Yamasaki, N., Kiya, M., Kadowaki, S., Sugimoto, D., Funayama, T., Someya, Y., Kakehi, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091154 · Cited by 9
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Mazzieri, A., & Marcon, L. M. R. (2025) · Biomedicines · doi:10.3390/biomedicines13092123 · Cited by 13
“In fact, dapagliflozin-induced glucose and weight loss are partially counteracted by a concomitant increase in glucagon and hence glucose synthesis of 32% and 17%, respectively, which might be one of the probable mechanisms mitigating the calorie deficit and attenuating weight loss [28].”
Bell, K. F., Katz, A., & Sheehan, J. (2016) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s108586 · Cited by 9
“The use of SGLT-2 inhibitor has been found to be associated with an increase in plasma glucagon concentration and endogenous glucose production (EGP), which may diminish the glucose-lowering effects of these agents.(47,48) This increase in EGP was shown to be potentially related to inhibition of SGLT-2 expressed in pa…”
Voigt, J. H., Lauritsen, K. M., Pedersen, S. B., Hansen, T. K., Møller, N., Jessen, N., LAURENTI, M. C., Man, C. D., Vella, A. V., Gormsen, L. C., et al. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13991 · Cited by 9
“3,4 Even though SGLT2 inhibitors thus exert their desired direct pharmacological effect in the kidneys, SGLT2 inhibitors also significantly affect other aspects of whole-body substrate metabolism.”
BackgroundSingh, A. K., Misra, A., Das, A. K., Behl, A., Srivastava, A., Paneerselvam, A., Chidambaram, B., Saboo, B., Sethi, B. K., Makkar, B. M., et al. (2023) · Journal of the Association of Physicians of India · doi:10.59556/japi.71.0422 · Cited by 12
“25,139 143 As a result, when taken with an SGLT2i, the dose of insulin and/or insulin secretagogues may need to be lowered to avoid hypoglycemia.”
Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
Dutta, D., & Kalra, S. (2014) · PubMed · Cited by 8
Mori‐Anai, K., Tashima, Y., Nakada, T., Nakamaru, Y., Takahata, T., & Saito, R. (2020) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2253 · Cited by 8
Kurinami, N., Sugiyama, S., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouch, K., Jinnouchi, T., Nomura, M., & Jinnouchi, H. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4401 · Cited by 8
Expression and mechanism of microRNA 195 in diabetic retinopathy
Li, S., Zhang, H., Han, Y., & Kuang, R. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0231 · Cited by 9
Moon, J. S., Kim, N. H., Na, J. O., Cho, J., Jeong, I., Lee, S. H., Mok, J., Kim, N. H., Chung, D. J., Cho, J., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0356 · Cited by 9
“In addition, it has been reported that SGLT-2 inhibitors paradoxically increase hepatic glucose production [24,25].”
Progress in the management of patients with diabetes and chronic kidney disease
Garcia, L. P., Thomas, S. S., Rajesh, H., & Navaneethan, S. D. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000811 · Cited by 10
“[12] demonstrated that a reduction of plasma glucose with the SGLT-2i works specifically on the kidney to induce glucosuria which improves muscle insulin sensitivity.”
BackgroundThirumathyam, R., Richter, E. A., Goetze, J. P., Fenger, M., van Hall, G., Dixen, U., Holst, J. J., Madsbad, S., Vejlstrup, N. G., Madsen, P. L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054100 · Cited by 10
Sun, W., Xing, Y., Kong, D., Zhang, Z., Ma, H., & Yang, L. (2022) · Medicine · doi:10.1097/md.0000000000030553 · Cited by 9
Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease
Lin, W.-R., Liu, K., Ling, T., Wang, M., & Lin, W. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.352 · Cited by 9
Alosaimi, M. E., Alotaibi, B. S., Abduljabbar, M. H., Alnemari, R. M., Almalki, A. H., & Serag, A. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116018 · Cited by 9
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0621-8 · Cited by 8
Singh‐Franco, D. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1004311 · Cited by 12
“Based on this observation, and the effect of incretin mimetics on glucagon suppression [27], the investigators hypothesized that a concomitant incretin-based therapy would counteract the increase in EGP and enhance glycemic efficacy of a SGLT2 inhibitor [25].”
BackgroundInfluentialGirard, J. R. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.006 · Cited by 12
Coppenrath, V. A., & Hydery, T. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017731111 · Cited by 9
Sodium–Glucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays Diagnosis
Leslie, B. R., Gerwin, L. E., & Taylor, S. I. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1463 · Cited by 9
Miyoshi, K., Aoyama, T., Kameda, S., Ishibashi, N., Sakai, Y., Yamanaka, T., Kawaguchi, T., Kadowaki, Y., & Yamauchi, T. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109068 · Cited by 9
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 9
Iwahashi, Y., Hirose, S., Nakajima, S., Seo, A., Takahashi, T., & Tamori, Y. (2016) · Diabetology International · doi:10.1007/s13340-016-0295-6 · Cited by 7
“action and secretion of insulin, and consequently decrease glucose toxicity and insulin resistance [4].”
The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia
Kim, M.-K., Lee, E. J., Shin, H., Jung, H. S., Kim, T. K., Kim, T. N., Kwon, M. J., Lee, S. H., Rhee, B. D., & Park, J. H. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0659-1 · Cited by 7
Lee, J., Hong, S., Kim, M.-J., Lim, Y.-M., Moon, S. J., Kwon, H., Park, S. E., Rhee, E., & Lee, W. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1786 · Cited by 7
“In patients with T2DM, the SGLT2 inhibitor dapagliflozin improves insulin sensitivity by reducing plasma glucose concentrations via glycosuria and increases endogenous glucose production by increasing the glucagon/insulin ratio [11].”
Nakamura, Y., Horie, I., Kitamura, T., Kusunoki, Y., Nishida, K., Yamamoto, A., Hirota, Y., Fukui, T., Maeda, Y., Minami, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15458 · Cited by 8
“18,19 It is widely known that people with T1D have an impaired counter-regulatory response of glucagon to hypoglycaemia.”
BackgroundClinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
Valentine, V., & Hinnen, D. A. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.1.5 · Cited by 9
Nagoya, T., Kamimura, K., Goto, R., Shinagawa‐Kobayashi, Y., Niwa, Y., Kimura, A., Sakai, N., Ko, M., Nishina, H., & Terai, S. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12734 · Cited by 7
Alsahli, M., Shrayyef, M. Z., & Gerich, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_2 · Cited by 12
Zhao, Y.-X., Borjigin, S., & Yan, Z.-L. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.224 · Cited by 7
Zyoud, S. H. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00497-4 · Cited by 11
Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach
Singh, A. K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.139214 · Cited by 9
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1229302 · Cited by 7
Messana, J. M., Schwartz, S. S., & Townsend, R. R. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s105721 · Cited by 7
Usui, M., Tanaka, M., & Takahashi, H. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100233 · Cited by 7
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Sanon, V., Patel, S., Sanon, S., Rodriguez, R., Pham, S., & Chilton, R. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s97619 · Cited by 6
“Another effect of SGLT2 inhibition is to reduce insulin resistance by alleviating glucotoxicity, which has been demonstrated with a minimum of 2 weeks of dapagliflozin treatment.(17) In totality, the effects of the negative energy balance, weight loss, reduction in blood pressure (BP), and edema are observed as a clas…”
BackgroundSGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
Asirvatham, A. R., Asirvatham, A. J., & Mahadevan, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0759 · Cited by 7
“43 Anti-inflammatory effects of SGLT2i have been proposed based on smaller studies and are not convincingly proven yet.”
Chen, X., Xiao, Z., Dai, N., & Fan, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1457268 · Cited by 6
Protective Mechanisms of SGLTi in Ischemic Heart Disease
Liao, L., Wang, T., Zhang, L., Yan, W., & Fan, X. (2024) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10513-x · Cited by 6
“EGG was similarly increased in nondiabetic subjects [25, 26].”
Schwartz, S. S., & Katz, A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s65588 · Cited by 8
“Dapagliflozin and other SGLT-2 inhibitors are associated with increases in endogenous glucose production and glucagon concentrations that appear to be independent of the reduction in plasma glucose by SGLT-2 inhibition and may partially blunt the glucose-lowering effects of SGLT-2 inhibitors.(47,48) SGLT-2 is expresse…”
Shigiyama, F., Hiruma, S., Hisatake, S., Shiraga, N., Ikeda, T., Hirose, T., & Kumashiro, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0640-4 · Cited by 6
Sato, D., Nakamura, T., Amarume, J., Yano, M., Nishina, A., Feng, Z., & Kusunoki, M. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.09.009 · Cited by 6
Effects of Sustained Hyperglycemia on Skeletal Muscle Lipids in Healthy Subjects
Shannon, C. E., Merovci, A., Fourcaudot, M. J., Tripathy, D., Abdul‐Ghani, M. A., Wang, H., Han, X., Norton, L., & DeFronzo, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac306 · Cited by 7
Self-citationTaha, M., Elazab, S. T., Qutub, A., Abdelbagi, O., Baokbah, T. A. S., Gomaa, A. S., Zaghloul, R. A., Albarakati, A. J. A., Qusty, N. F., Babateen, O., et al. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2023.2266736 · Cited by 8
“Besides its antidiabetic properties, it exhibits a cytoprotective effect as it decreases blood pressure [10], lowers body weight [11], and decreases resistance to insulin [12].”
BackgroundGetting to goal in newly diagnosed type 2 diabetes using combination drug “subtraction therapy”
Jennings, A. S., Lovett, A. J., George, T. M., & Jennings, J. S. (2015) · Metabolism · doi:10.1016/j.metabol.2015.04.008 · Cited by 7
“be demonstrated as a short-term phenomenon [18,19], it is not an relevant issue in treating newly diagnosed patients, as they rapidly decreased their blood glucose and HbA1c levels at a speed suggesting that these defects were completely or”
BackgroundYassin, S. A., & Aroda, V. R. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s121899 · Cited by 7
SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10087 · Cited by 7
Evolution of Glucose-Lowering Drugs for Type 2 Diabetes
Krentz, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00033-7 · Cited by 8
Rational combination therapy for type 2 diabetes
Prato, S. D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30069-5 · Cited by 6
Qin, Y., Adams, J. M., Solis‐Herrera, C., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2020) · Diabetes Care · doi:10.2337/dc19-1993 · Cited by 7
Self-citationYamasaki, N., Tamura, Y., Kaga, H., Sato, M., Kiya, M., Kadowaki, S., Suzuki, R., Furukawa, Y., Sugimoto, D., Funayama, T., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14312 · Cited by 9
Kuhre, R. E., Deacon, C. F., Albrechtsen, N. J. W., & Holst, J. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14422 · Cited by 8
Early prescription of SGLT2i for acute patient care: from current evidence to future directions
Ricci, F., Saraullo, S., Boccatonda, A., Sorella, A., Cipollone, A., Simeone, P., Gallina, S., Santilli, F., Cipollone, F., & D’Ardes, D. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103081 · Cited by 6
Popoviciu, M. S., Păduraru, L., Rahman, M., Supti, F. A., Stoica, R. A., Reurean‐Pintilei, D., Bica, C. I., & Cavalu, S. D. (2024) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1439 · Cited by 8
“The potential mechanisms by which SGLT2 inhibitors improve β-cell function and reduce insulin resistance in T2D patients have been examined in recent research [51]. o Insulin resistance and inflammation are reduced by SGLT2 inhibitors through polarizing M2 macrophages.”
Prediabetes and CKD: Does a causal relationship exist
Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología · doi:10.1016/j.nefro.2024.06.008 · Cited by 8
“69,73–75”
Sato, D., Nakamura, T., Amarume, J., Yano, M., Umehara, Y., Nishina, A., Tsutsumi, K., Feng, Z., & Kusunoki, M. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220307153618 · Cited by 6
Radellini, S., Vigneri, E., Guarnotta, V., Pantò, F., & Giordano, C. S. D. S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01056-4 · Cited by 5
Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15404 · Cited by 5
Self-citationThirumathyam, R., Richter, E. A., van Hall, G., Holst, J. J., Fenger, M., Goetze, J. P., Dixen, U., Vejlstrup, N. G., Madsbad, S., Madsen, P. L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02094-x · Cited by 6
“It also increases glucagon release, hepatic glucose production, lipolysis, ketogenesis and lipid oxidation, i.e. metabolic changes opposite to those found with insulin treatment [18, 19].”
BackgroundSohn, T. S., Han, K. A., Kim, Y., Lee, B., Chon, S., Jeong, I., Hong, E., Son, J. W., Na, J., Cho, J. M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15537 · Cited by 5
“18 The beneficial effect of SGLT-2 inhibitors on insulin sensitivity is attributed to lowering plasma glucose through enhanced glycosuria, 26 – 28 and the persistence of the enavogliflozin effect on HOMA-IR might be linked with the above-mentioned fact that this drug exerts a more potent effect on…”
BackgroundEffect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects
Chen, X., Tripathy, D., CHILTON, R. J., HANSIS-DIARTE, A. A., Salehi, M., Solis‐Herrera, C., Cersósimo, E., & DeFronzo, R. A. (2024) · Diabetes · doi:10.2337/db23-0457 · Cited by 6
Self-citationDapagliflozina: Más allá del control glucémico en el tratamiento de la diabetes mellitus tipo 2
Sanz-Serra, P., Pedro‐Botet, J., Roux, J. A. F., Benaiges, D., & Chillarón, J. J. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.11.001 · Cited by 11
Kakuda, H., Kobayashi, J., Sakurai, M., Kakuda, M., & Takekoshi, N. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2806w · Cited by 5
Kurozumi, A., Okada, Y., & Tanaka, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0577 · Cited by 5
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Li, J., Zhou, L., & Gong, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903902 · Cited by 6
Torimoto, K., Okada, Y., Goshima, Y., Tokutsu, A., Sato, Y., & Tanaka, Y. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13770 · Cited by 5
Wang, C., Chang, C.-W., Lu, Y., Lam, H., Ku, S.-J., Tseng, K.-B., & Kao, Y.-H. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.11.015 · Cited by 5
Moreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thévenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J. A., Pattou, F. N., Bonner, C., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16089 · Cited by 7
“22,23,31,32 To explore the effects of SGLT2i on these hormone levels and their influence on metabolic pathways, we administered dapagliflozin chronically to diet-induced insulin-resistant mice, alongside a control group treated with vehicle.”
InfluentialPersonalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967319 · Cited by 5
Self-citationSGLT2i Increase Endogenous Glucose Production: That’s Good News!
Giaccari, A. (2022) · Diabetes Care · doi:10.2337/dci22-0010 · Cited by 4
Ferreira, A., Emara, A. F., Herzig, D., Melmer, A., Vogt, A. P., Nakas, C. T., Facchinetti, A., Man, C. D., & Bally, L. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060668 · Cited by 5
Khalifa, M. K. A., Dawaba, A. M., Dawaba, H. M., Al‐Najjar, A. H., Elzaitony, A. S., Fouad, F. A., Soliman, M. M., & Nasr, Z. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104257 · Cited by 4
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.